Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 1 (2004), Issue 4 (November)

1. Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings.
   Radiology, 233(2): 433-40. [Abstract] [Full-text]
2. Hemolytic uremic syndrome presenting after treatment of endodermal sinus tumor.
   Obstet Gynecol, 104(5): 1184-7. [Abstract] [Full-text]
3. Abdominal compartment syndrome secondary to ovarian mucinous cystadenoma.
   Obstet Gynecol, 104(5): 1180-2. [Abstract] [Full-text]
4. Coccidioidomycosis mimicking ovarian cancer.
   Obstet Gynecol, 104(5): 1177-9. [Abstract] [Full-text]
5. Paraneoplastic limbic encephalitis: ovarian cancer presenting as an amnesic syndrome.
   Obstet Gynecol, 104(5): 1174-7. [Abstract] [Full-text]
6. Port-site implantation after laparoscopic treatment of borderline ovarian tumors.
   Obstet Gynecol, 104(5): 1167-70. [Abstract] [Full-text]
7. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers.
   Nat Med, 10(11): 1251-6. [Abstract] [Full-text]
8. Women's satisfaction with genetic counseling for hereditary breast-ovarian cancer: psychological aspects.
   Am J Med Genet A, 131(1): 36-41. [Abstract] [Full-text]
9. Overexpression of a hybrid gene consisting of the amino-terminal fragment of urokinase and carboxyl-terminal domain of bikunin suppresses invasion and migration of human ovarian cancer cells in vitro.
   Int J Cancer, 113(1): 54-8. [Abstract] [Full-text]
10. Angiogenesis and vascular survival ability in ovarian adenocarcinomas.
    Virchows Arch, 445(5): 521-6. [Abstract] [Full-text]
11. Endothelin-1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion.
    J Biol Chem, 279(45): 46700-5. [Abstract] [Full-text]
12. Thrombocytopenia associated with second-line carboplatin-based chemotherapy for ovarian, fallopian tube, and primary peritoneal cavity cancers.
    J Cancer Res Clin Oncol, 130(12): 741-4. [Abstract] [Full-text]
13. Mutation of the PIK3CA gene in ovarian and breast cancer.
    Cancer Res, 64(21): 7678-81. [Abstract] [Full-text]
14. Ovarian teratoma with diffused peritoneal reactions mimicking advanced ovarian malignancy.
    Arch Gynecol Obstet, 270(3): 189-91. [Abstract] [Full-text]
15. Human KIT ligand promoter is positively regulated by HMGA1 in breast and ovarian cancer cells.
    Oncogene, 23(52): 8557-62. [Abstract] [Full-text]
16. Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGFbeta-RII, KRAS2, TP53 and/or CDNK2A.
    Cancer Chemother Pharmacol, 54(6): 497-504. [Abstract] [Full-text]
17. Gonadotropin (LH, FSH) levels in serum and cyst fluid in epithelial tumors of the ovary.
    Arch Gynecol Obstet, 270(3): 151-6. [Abstract] [Full-text]
18. A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer.
    Invest New Drugs, 23(1): 85-9. [Abstract] [Full-text]
19. Evaluation of genomic changes in a large series of malignant ovarian germ cell tumors--relation to clinicopathologic variables.
    Cancer Genet Cytogenet, 155(1): 25-32. [Abstract] [Full-text]
20. Nodal induces apoptosis and inhibits proliferation in human epithelial ovarian cancer cells via activin receptor-like kinase 7.
    J Clin Endocrinol Metab, 89(11): 5523-34. [Abstract] [Full-text]
21. Overexpression of follicle-stimulating hormone receptor activates oncogenic pathways in preneoplastic ovarian surface epithelial cells.
    J Clin Endocrinol Metab, 89(11): 5508-16. [Abstract] [Full-text]
22. A multicenter study of supportive-expressive group therapy for women with BRCA1/BRCA2 mutations.
    Cancer, 101(10): 2327-40. [Abstract] [Full-text]
23. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference?
    Cancer, 101(10): 2214-21. [Abstract] [Full-text]
24. Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer.
    Arch Intern Med, 164(20): 2253-9. [Abstract] [Full-text]
25. Antiproliferative effects of interferon-alphaCon1 on ovarian clear cell adenocarcinoma in vitro and in vivo.
    Clin Cancer Res, 10(21): 7418-26. [Abstract] [Full-text]
26. Psychosocial impact of breast/ovarian (BRCA1/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort.
    Br J Cancer, 91(10): 1787-94. [Abstract] [Full-text]
27. BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study.
    Br J Cancer, 91(10): 1829-34. [Abstract] [Full-text]
28. A novel nonradioactive method for measuring aromatase activity using a human ovarian granulosa-like tumor cell line and an estrone ELISA.
    Toxicol Sci, 82(2): 443-50. [Abstract] [Full-text]
29. Telomere-mediated mitotic disturbances in immortalized ovarian epithelial cells reproduce chromosomal losses and breakpoints from ovarian carcinoma.
    Genes Chromosomes Cancer, 42(1): 22-33. [Abstract] [Full-text]
30. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
    J Clin Oncol, 22(22): 4523-31. [Abstract] [Full-text]
31. Biomarkers of ovarian tumours.
    Eur J Cancer, 40(17): 2604-12. [Abstract] [Full-text]
32. Survivin interacts with Smac/DIABLO in ovarian carcinoma cells but is redundant in Smac-mediated apoptosis.
    Exp Cell Res, 302(1): 69-82. [Abstract] [Full-text]
33. Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study.
    J Clin Oncol, 22(22): 4595-603. [Abstract] [Full-text]
34. Serum bioactive lysophospholipids prevent TRAIL-induced apoptosis via PI3K/Akt-dependent cFLIP expression and Bad phosphorylation.
    Cell Death Differ, 11(12): 1287-98. [Abstract] [Full-text]
35. Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing.
    Ann Oncol, 15(12): 1834-41. [Abstract] [Full-text]
36. Characterization of a carcinogenesis rat model of ovarian preneoplasia and neoplasia.
    Cancer Res, 64(22): 8177-83. [Abstract] [Full-text]
37. Association between fertility drugs and gynecologic cancers, breast cancer, and childhood cancers.
    Acta Obstet Gynecol Scand, 83(12): 1104-11. [Abstract] [Full-text]
38. Interferon-gamma expression is an independent prognostic factor in ovarian cancer.
    Am J Obstet Gynecol, 191(5): 1598-605. [Abstract] [Full-text]
39. The epigenetics of ovarian cancer drug resistance and resensitization.
    Am J Obstet Gynecol, 191(5): 1552-72. [Abstract] [Full-text]
40. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
    J Natl Cancer Inst, 96(22): 1682-91. [Abstract] [Full-text]
41. The role of BRCA1 in the cellular response to chemotherapy.
    J Natl Cancer Inst, 96(22): 1659-68. [Abstract] [Full-text]
42. Psychological response to test results in an ovarian cancer screening program: a prospective, longitudinal study.
    Health Psychol, 23(6): 622-30. [Abstract] [Full-text]
43. Sample classification from protein mass spectrometry, by 'peak probability contrasts'.
    Bioinformatics, 20(17): 3034-44. [Abstract] [Full-text]
44. A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs.
    Am J Epidemiol, 160(11): 1070-8. [Abstract] [Full-text]
45. HPLC-RIA analysis of steroid hormone profile in a virilizing stromal tumor of the ovary.
    J Biochem Biophys Methods, 61(1): 47-56. [Abstract] [Full-text]
46. TP53 status determines clinical significance of ERBB2 expression in ovarian cancer.
    Br J Cancer, 91(11): 1916-23. [Abstract] [Full-text]
47. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations.
    Br J Cancer, 91(11): 1911-5. [Abstract] [Full-text]
48. Virilisation in a case of transitional cell carcinoma of the ovary.
    J Clin Pathol, 57(12): 1331-2. [Abstract] [Full-text]
49. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer.
    Mol Ther, 10(6): 1032-42. [Abstract] [Full-text]
50. An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients.
    Oncogene, 23(55): 8859-67. [Abstract] [Full-text]
51. Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples.
    Int J Cancer, 113(3): 372-8. [Abstract] [Full-text]
52. A rationale for neoadjuvant systemic treatment followed by surgical assessment and intraperitoneal chemotherapy in patients presenting with non-surgically resectable ovarian or primary peritoneal cancers.
    J Cancer Res Clin Oncol, 131(1): 26-30. [Abstract] [Full-text]
53. Active recruitment increased enrollment in a hereditary cancer registry.
    J Clin Epidemiol, 57(11): 1172-6. [Abstract] [Full-text]
54. Inhibin-producing ovarian granulosa cell tumor as a cause of secondary amenorrhea: case report and review of the literature.
    J Obstet Gynaecol Res, 30(6): 439-43. [Abstract] [Full-text]
55. Use of heparin to lower the incidence of phlebitis induced by anti-neoplastic agents used in ovarian cancer.
    J Obstet Gynaecol Res, 30(6): 427-9. [Abstract] [Full-text]
56. Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
    Clin Cancer Res, 10(22): 7645-54. [Abstract] [Full-text]
57. Recurrent ovarian cancer: how important is it to treat to disease progression?
    Clin Cancer Res, 10(22): 7439-49. [Abstract] [Full-text]
58. Presence of nanobacteria in psammoma bodies of ovarian cancer: evidence for pathogenetic role in intratumoral biomineralization.
    Histopathology, 45(6): 633-7. [Abstract] [Full-text]
59. Gene expression signature with independent prognostic significance in epithelial ovarian cancer.
    J Clin Oncol, 22(23): 4700-10. [Abstract] [Full-text]

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.